Corindus Vascular Robotics
announced the results of the first clinical study of the CorPath 200 System. The CorPath 200 is a medical device that offers interventional cardiologists complete PCI (percutaneous coronary intervention) procedure control from an interventional cockpit.
The trial - the first "in-human clinical study" of the CorPath 200 System - was conducted on eight patients to evaluate the safety and technical efficacy of the system in delivering and manipulating coronary guidewires and stent/balloon systems in PCI procedures.
The experiment demonstrated the CorPath 200 System's ability to deliver a guidewire and other angioplasty devices to a target lesion in a highly controlled manner.
The research was conducted at the Corbic Research Institute, Envigado, Colombia.
Corindus CEO David Handler was pleased with the results, stating that the ergonomic design of the CorPath 200 System improves the physician's ability to focus, enhances visualization, and offers precise robotic-assisted control.
"The first-in-human clinical study of the CorPath 200 System shows that for the first time a physician can execute an entire PCI procedure precisely and accurately without the pain, distraction and fatigue of manual procedures," he stated.
"We're extremely excited about the progress we continue to make in bringing the CorPath 200 System to market," Handler added. "We're even more excited about what this means for physicians and patients. We believe that a new robotic tool that improves procedure execution will ultimately help to further improve outcomes."